<DOC>
	<DOCNO>NCT03099382</DOCNO>
	<brief_summary>In study , participant advance metastatic squamous cell carcinoma esophagus progress first-line standard therapy randomize receive either single agent SHR-1210 Investigator 's choice standard therapy docetaxel irinotecan . The primary study hypothesis treatment SHR-1210 prolong overall survival ( OS ) compare treatment standard therapy .</brief_summary>
	<brief_title>Study SHR-1210 Versus Investigator 's Choice Standard Therapy Participants With Advanced Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>1. age:1875 year , male femal . 2 . Histologically cytologically confirm Squamous Cell Carcinoma Esophagus , locally advanced , unresectable disease Metastatic disease . 3 . Fail firstline standard therapy . 4 . Measurable disease base Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 . 5 . Can provide either newly obtain archival tumor tissue sample . 6 . ECOG 01 . 7 . Life expectancy great 12 week . 8 . Adequate organ function . 9 . Female : child bear potential , negative urine serum pregnancy test result within 72 h study treatment . Participants reproductive potential must willing use adequate contraception course study 3 month last dose SHR1210 180 day last dose docetaxel irinotecan . 10 . Patient give write informed consent . 1 . Has know additional malignancy within last 5 year study treatment exception curatively treat basal cell squamous cell carcinoma skin and/or curatively resect insitu cervical and/or breast cancer . 2 . Known central nervous system ( CNS ) metastases . 3 . Subjects active autoimmune disease history autoimmune disease . 4 . Uncontrolled clinically significant heart disease , include limited following : ( 1 ) &gt; NYHA II congestive heart failure ; ( 2 ) unstable angina , ( 3 ) myocardial infarction within past 1 year ; ( 4 ) clinically significant supraventricular arrhythmia ventricular arrhythmia requirement treatment intervention ; 5 . Active infection unexplained fever &gt; 38.5°C screen first schedule day dose ( subject tumor fever may enrol discretion investigator ) ; 6 . History Interstitial Pneumonia active noninfectious pneumonitis . 7 . Known Human Immunodeficiency Virus ( HIV ) infection、active Hepatitis B Hepatitis C. 8 . Prior therapy PD1 , antiPDLigand 1 ( PDL1 ) agent . 9 . Known history hypersensitivity macromolecular protein preparation component SHR1210 formulation , allergy , hypersensitivity , contraindication docetaxel , irinotecan . 10 . Concurrent medical condition require use cortisol ( ＞10mg/day Prednisone equivalent dose ) systematic immunosuppressive medication within 14 day study treament . Except : inhalation topical corticosteroid . Doses &gt; 10 mg/day prednisone equivalen replacement therapy . 11 . Has receive prior anticancer monoclonal antibody ( mAb ) , chemotherapy , target small molecule therapy , radiation therapy within 4 week prior study Day 1 recover adverse event due previously administer agent . 12 . Currently participate participate study within 4 week first dose study medication . 13 . Received live vaccine within 4 week first dose study medication . 14 . Pregnancy breast feed . 15 . According investigator , condition may lead stop research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>